REGENXBIO Inc. Stock News

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Prudential Financial Inc. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,999 shares of the biotechnology companys stock after selling 1,131 shares during the quarter. Prudential Financial Inc.s holdings in REGENXBIO were worth $1,515,000 []

The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne).  Duchenne is a genetic disorder

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been given a consensus recommendation of Buy by the ten brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average []

Related Stocks: IAC , ENTA , RGNX , IVV , WH , EOLS , IMCR , FCOB , MRSN , IMUX , BKCC , NEXI , HUM , GRA , ASND , NWHM , MUDS , BPY ,

Related Stocks: DRNA , RGNX , ARWR , AMYT , ARVN , NGM , HARP , GLPG ,

REGENXBIO Inc. (NASDAQ:RGNX) has been given a consensus recommendation of Buy by the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 []

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

REGENXBIO's (RGNX) CEO Ken Mills on Q3 2021 Results - Earnings Call Transcript

The average of price targets set by Wall Street analysts indicates a potential upside of 77.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the posi

Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME).  The data were

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events No intraocular inflammation observ

REGENXBIO stock declined by 20% yesterday, while it is down 26% in the last ten trading days. In comparison, the broader S&P500 index declined by 1.4% over the same period.

ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events Positive initial data from Coho

ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE®) to be presented REG